Direct Oral Anticoagulants versus Standard Therapy in Upper Extremity Deep Vein Thrombosis: Real-World Evidence
Direkte orale Antikoagulanzien versus Standardtherapie bei tiefer Venenthrombose der oberen Extremität: Real-World-Evidence
Thrombosis and Haemostasis · 01.03.2026 · 126 (03) · 287-296
DOI: 10.1055/a-2615-4513 ↗Auf einen Blick
Eine Beobachtungsanalyse aus dem RIETE-Register untersuchte DOACs bei UEDVT. Das kombinierte Ereignis trat unter DOACs seltener auf als unter Standardtherapie.
Fragestellung
Wie sind Wirksamkeit und Sicherheit von DOACs im Vergleich zur Standardtherapie bei UEDVT im Versorgungsalltag?
Methode
Beobachtungsanalyse im RIETE-Datensatz; UEDVT-Patient:innen mit DOACs oder Standardtherapie; Ereignisse in den ersten 5 Tagen ausgeschlossen; Adjustierung mit multivariablen und multilevel Analysen.
Ergebnisse
3.496 UEDVT-Patient:innen zwischen Januar 2011 und November 2023. Kombiniertes Outcome: 1,0 % unter DOACs vs. 2,8 % unter Standardtherapie; adjustierte Subhazard Ratio 0,41 (95 %-KI 0,19–0,90).
Schlussfolgerung der Autor:innen
Die Autor:innen sehen einen möglichen Zusammenhang zwischen DOACs und einem geringeren Risiko für VTE-Rezidiv und schwere Blutung im Vergleich zur Standardtherapie bei UEDVT.
Kernaussagen
- Kombiniertes Outcome seltener unter DOACs als unter Standardtherapie
- Adjustierte Subhazard Ratio 0,41 (95 %-KI 0,19–0,90)
- Sensitivitätsanalysen nach Krebs und katheterassoziierter Thrombose konsistent
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Beobachtungsstudie in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.03.2026. Verfasst von Pedro Ruiz-Artacho und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Clínica Universidad de Navarra, Madrid, Spain. Hauptthemen laut MEDLINE: Anticoagulants, Upper Extremity Deep Vein Thrombosis, Factor Xa Inhibitors, Venous Thrombosis. Die Arbeit nennt 32 Literaturangaben.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Evidence on the use of direct oral anticoagulants (DOACs) in upper extremity deep vein thrombosis (UEDVT) remains limited. This study examines real-world outcomes of DOACs compared with standard anticoagulation therapy for UEDVT patients. Using the RIETE (Registro Informatizado de Enfermedad TromboEmbólica) database, we conducted an observational analysis of UEDVT patients treated with DOACs or standard therapy (low molecular weight heparin [LMWH] or vitamin K antagonists for noncancer patients, and LMWH for cancer patients). Patients with events during the first 5 days of treatment were excluded. The primary outcome was a composite of venous thromboembolism (VTE) recurrence and major bleeding during the first 3 months of therapy. Multivariable and multilevel analyses were conducted to adjust for confounding. Between January 2011 and November 2023, 3,496 UEDVT patients met the inclusion criteria. Of these, 679 (19.4%) received DOACs, whereas 2,817 (80.6%) received standard therapy. The composite outcome occurred in seven patients (1.0%) on DOACs (5 [0.7%] VTE recurrence, 2 [0.3%] major bleeding) compared with 78 patients (2.8%) on standard therapy (51 [1.8%] VTE recurrence, 29 [1.0%] major bleeding; p < 0.001). Multivariable analysis showed that DOAC use was associated with a lower risk of the composite outcome (adjusted subhazard ratio: 0.41; 95% confidence interval: 0.19–0.90). These findings remained consistent in multilevel models and sensitivity analyses stratified by cancer and catheter-related thrombosis. This real-world analysis suggests that DOACs may be associated with a lower risk of VTE recurrence and major bleeding compared with standard therapy in patients with UEDVT. These findings support DOACs as a viable treatment option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Clínica Universidad de Navarra, Madrid, Spain.
- Interdisciplinar Teragnosis and Radiosomics Research Group (INTRA-Madrid), Universidad de Navarra, Madrid, Spain.
- CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain.
- Department of Haematology, Clínica Universidad de Navarra, Pamplona, Spain.
- CIBER Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
- Department of Internal Medicine, Hospital General Universitario Santa Lucía, Cartagena, Murcia, Spain.
ORCID-Profile: Pedro Ruiz-Artacho, Ramón Lecumberri, Covadonga Gómez-Cuervo, Marijan Bosevski
Zitieren
APA
Ruiz-Artacho, P., Lecumberri, R., Trujillo-Santos, J., Beddar Chaib, F., Moustafa, F., Lorenzo, A., Gómez-Cuervo, C., Bosevski, M., Monreal, M., & RIETE Investigators (2026). Direct Oral Anticoagulants versus Standard Therapy in Upper Extremity Deep Vein Thrombosis: Real-World Evidence. Thrombosis and Haemostasis, 126(03), 287-296. https://doi.org/10.1055/a-2615-4513
Vancouver
Ruiz-Artacho P, Lecumberri R, Trujillo-Santos J, Beddar Chaib F, Moustafa F, Lorenzo A, et al. Direct Oral Anticoagulants versus Standard Therapy in Upper Extremity Deep Vein Thrombosis: Real-World Evidence. Thrombosis and Haemostasis. 2026;126(03):287-296. doi:10.1055/a-2615-4513
BibTeX
@article{RuizArtacho2026,
author = {Ruiz-Artacho, Pedro and Lecumberri, Ramón and Trujillo-Santos, Javier and Beddar Chaib, Fahd and Moustafa, Farès and Lorenzo, Alicia and Gómez-Cuervo, Covadonga and Bosevski, Marijan and Monreal, Manuel and RIETE Investigators, RIETE Investigators},
title = {Direct Oral Anticoagulants versus Standard Therapy in Upper Extremity Deep Vein Thrombosis: Real-World Evidence},
journal = {Thrombosis and Haemostasis},
year = {2026},
volume = {126},
number = {03},
pages = {287--296},
doi = {10.1055/a-2615-4513}
}
EUVIMED